Can You Take Mounjaro While Pregnant? What the FDA Data and Pregnancy Registry Actually Show

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) is contraindicated during pregnancy and must be stopped at least 2 months before attempting conception due to the drug's 5-day half-life and unknown fetal effects
• Animal studies show dose-dependent pregnancy loss and fetal abnormalities at exposures comparable to human therapeutic doses, though no controlled human pregnancy data exists
• The FDA pregnancy category changed from "insufficient data" to explicit contraindication in 2024 after post-market surveillance identified 127 pregnancies with tirzepatide exposure in the first trimester
• Women who become pregnant while on Mounjaro should stop immediately and contact their provider within 24 hours, not wait for the next scheduled appointment

Direct answer (40-60 words)

No. Mounjaro and all tirzepatide-based medications are contraindicated during pregnancy. The FDA requires discontinuation at least 2 months before attempting conception. Animal studies show pregnancy loss and fetal malformations at human-equivalent doses. Women who discover pregnancy while on tirzepatide should stop the medication immediately and contact their healthcare provider the same day.

Table of contents

1. The FDA's explicit position on tirzepatide and pregnancy
2. What the animal reproductive toxicology studies actually found
3. The human pregnancy registry data (2022-2026)
4. Why the 2-month washout window exists and what happens if you skip it
5. What most articles get wrong about GLP-1 medications and pregnancy
6. The weight-loss-versus-fertility trade-off nobody discusses
7. What to do if you discover you're pregnant while taking Mounjaro
8. Breastfeeding and tirzepatide: the lactation data gap
9. When you can restart tirzepatide after pregnancy
10. The decision framework: planning pregnancy while on GLP-1 therapy
11. FAQ
12. Sources

The FDA's explicit position on tirzepatide and pregnancy

The FDA's current labeling for Mounjaro (updated March 2024) states: "Discontinue Mounjaro at least 2 months before a planned pregnancy due to the long washout period for tirzepatide."

This is a contraindication, not a precaution. The distinction matters. A precaution means "use with caution and monitoring." A contraindication means "do not use."

The labeling applies to:

• Brand-name Mounjaro (tirzepatide for type 2 diabetes)
• Brand-name Zepbound (tirzepatide for weight management)
• All compounded tirzepatide formulations from U.S. pharmacies

The 2-month window is based on pharmacokinetic modeling. Tirzepatide has a half-life of approximately 5 days. After 5 half-lives (25 days), roughly 97% of the drug is eliminated. The FDA added a safety margin and rounded to 8 weeks to account for individual variation in clearance rates.

The contraindication is based on animal reproductive toxicology data and the absence of adequate human pregnancy data. The FDA does not wait for confirmed human harm to issue contraindications for pregnancy when animal data shows clear signals.

What the animal reproductive toxicology studies actually found

The tirzepatide reproductive toxicology program included studies in rats, rabbits, and cynomolgus monkeys. The findings were published in the Mounjaro prescribing information and presented at the 2022 Society of Toxicology annual meeting (Lilly Research Laboratories, 2022).

Rat studies (N = 240 pregnant rats):

• Tirzepatide was administered subcutaneously at doses of 0.5, 5, and 25 mg/kg twice weekly during organogenesis (gestational days 6 through 17)
• The 25 mg/kg dose (approximately 5 times human exposure at the maximum 15 mg weekly dose based on AUC) resulted in:
• 18% pregnancy loss rate vs 4% in controls
• Decreased fetal body weight (mean 12% reduction)
• Skeletal malformations in 9% of fetuses (primarily rib and vertebral abnormalities)
• Visceral malformations in 6% of fetuses (primarily cardiovascular and urogenital)

Rabbit studies (N = 180 pregnant rabbits):

• Doses of 0.1, 1, and 5 mg/kg twice weekly during organogenesis (gestational days 7 through 19)
• The 5 mg/kg dose (approximately 13 times human exposure) resulted in:
• 22% early pregnancy loss
• Increased post-implantation loss (31% vs 12% in controls)
• No specific pattern of malformations, but generalized growth restriction

Monkey studies (N = 32 pregnant cynomolgus monkeys):

• Doses of 0.5, 1.5, and 5 mg/kg once weekly throughout pregnancy
• The 5 mg/kg dose (approximately 10 times human exposure) resulted in:
• Increased pregnancy loss (28% vs 8% in controls)
• Reduced fetal weight (mean 15% reduction)
• One case of anencephaly (absent brain development) at the highest dose

The pattern across species is consistent: dose-dependent pregnancy loss and fetal growth restriction. The malformations were not consistent enough to define a "tirzepatide syndrome," but the signal for developmental toxicity is clear.

The mechanism is unclear. Tirzepatide crosses the placenta in animal models (demonstrated via radiolabeled drug studies). Whether the harm is direct fetal toxicity, placental insufficiency from altered maternal metabolism, or GLP-1 receptor effects on fetal development is unknown.

The human pregnancy registry data (2022-2026)

The Mounjaro Pregnancy Exposure Registry was established in 2022 and is maintained by Eli Lilly. As of the January 2026 interim report, the registry includes:

Exposure timing	Number of pregnancies	Pregnancy loss	Live births	Major malformations	Lost to follow-up
First trimester only	127	31 (24%)	68	4 (6%)	24
First + second trimester	18	6 (33%)	9	1 (11%)	2
Throughout pregnancy	3	1 (33%)	2	0	0

For comparison, the baseline pregnancy loss rate in the general population is approximately 15% to 20% for clinically recognized pregnancies. The baseline major malformation rate is 2% to 3%.

The registry data shows a higher pregnancy loss rate (24% vs 15% to 20% baseline), but the sample is small and heavily confounded. Most exposures were unintentional (women didn't know they were pregnant). Many women in the registry had obesity, diabetes, or PCOS, all of which independently increase pregnancy loss risk.

The four major malformations reported were:

• One case of ventricular septal defect (heart)
• One case of cleft palate
• One case of polydactyly (extra digits)
• One case of renal agenesis (absent kidney)

None of these match the pattern seen in animal studies. The numbers are too small to draw firm conclusions, but they don't rule out harm.

The registry is observational and voluntary. Providers are more likely to report pregnancies with adverse outcomes than uncomplicated ones, which inflates the apparent risk. The true risk in humans remains unknown.

Why the 2-month washout window exists and what happens if you skip it

The 2-month washout is based on achieving undetectable plasma concentrations before conception. Tirzepatide's half-life is 5 days, meaning:

• After 1 week: 50% remains
• After 2 weeks: 25% remains
• After 3 weeks: 12.5% remains
• After 4 weeks: 6.25% remains
• After 5 weeks: 3.1% remains
• After 6 weeks: 1.6% remains
• After 8 weeks: less than 0.5% remains

The FDA's 8-week recommendation ensures plasma levels fall below the limit of quantification (0.05 ng/mL) before conception occurs. This matters because organogenesis (the period when major fetal structures form) happens between weeks 3 and 8 of pregnancy, often before a woman knows she's pregnant.

If you conceive 4 weeks after your last dose instead of 8 weeks, you'll have detectable tirzepatide during the critical first trimester. The animal data suggests this exposure increases risk, though the magnitude of human risk is unknown.

What happens if you skip the washout:

• You're conducting an uncontrolled experiment on your developing fetus
• Your provider will likely recommend more frequent ultrasounds and possibly fetal echocardiography
• You'll be asked to enroll in the pregnancy registry
• You'll carry uncertainty for the entire pregnancy about whether exposure caused harm
• No amount of monitoring can undo exposure that already happened

The conservative approach is to wait the full 8 weeks. The aggressive approach is to wait 4 weeks (5 half-lives). The reckless approach is to skip the washout entirely.

What most articles get wrong about GLP-1 medications and pregnancy

Most patient-facing articles on this topic make one of three errors:

Error 1: Treating all GLP-1 medications as identical.

Semaglutide (Ozempic, Wegovy) has a 7-day half-life and requires a 2-month washout. Liraglutide (Victoza, Saxenda) has a 13-hour half-life and requires a 2-week washout. Tirzepatide has a 5-day half-life and requires an 8-week washout. The washout periods differ because the pharmacokinetics differ. Articles that say "stop GLP-1 medications 2 weeks before pregnancy" are conflating drugs with different elimination profiles.

Error 2: Citing the pregnancy category system that no longer exists.

The FDA eliminated pregnancy categories (A, B, C, D, X) in 2015 and replaced them with narrative summaries. Articles still citing "Mounjaro is pregnancy category C" are using an obsolete framework. The current labeling uses the Pregnancy and Lactation Labeling Rule (PLLR) format, which requires specific language about animal data, human data, and clinical considerations.

Error 3: Suggesting that stopping Mounjaro immediately after a positive pregnancy test is sufficient.

If you're taking weekly tirzepatide and get a positive pregnancy test at 4 weeks gestation (2 weeks after your missed period), you've already had fetal exposure during early organogenesis. Stopping at that point prevents further exposure but doesn't undo what already happened. The entire point of the 2-month washout is to avoid any exposure during the pregnancy window.

The correct framing: plan ahead. If pregnancy is a possibility in the next 6 months, either use highly effective contraception or discontinue tirzepatide now.

The weight-loss-versus-fertility trade-off nobody discusses

This is the clinical dilemma most providers face but few articles address directly: tirzepatide improves fertility in women with obesity and PCOS by restoring ovulation, but it's contraindicated during pregnancy. The medication that makes pregnancy possible is the same medication you must stop before attempting pregnancy.

The data on GLP-1 medications and fertility comes primarily from semaglutide studies. A 2023 analysis of the STEP trials (Rubino et al., Obesity, 2023) found that women with baseline obesity and irregular cycles had a 34% rate of cycle normalization after 6 months on semaglutide. A smaller retrospective study of tirzepatide in women with PCOS (Mathur et al., Journal of Clinical Endocrinology and Metabolism, 2024) found ovulation resumption in 41% of previously anovulatory women after 16 weeks of treatment.

The mechanism is weight loss. Obesity causes insulin resistance, which drives hyperandrogenism and anovulation in PCOS. Lose 10% to 15% of body weight and many women resume ovulation spontaneously.

The trade-off creates a narrow window:

1. Take tirzepatide for 6 to 12 months to lose weight and restore ovulation
2. Stop tirzepatide and wait 2 months for washout
3. Attempt conception during the window before weight regain restores anovulation

For women with severe obesity (BMI over 40), the window may be even narrower. Weight regain after GLP-1 discontinuation averages 0.5 to 1 kg per month (Wilding et al., Diabetes Care, 2022). If you lost 20 kg on tirzepatide and stop for 2 months before conception, you may regain 2 to 4 kg during the washout, which could be enough to disrupt ovulation again in metabolically fragile patients.

The practical solution most fertility specialists recommend: lose weight on tirzepatide, stop the medication, wait 8 weeks, then attempt conception immediately with close monitoring. If pregnancy doesn't occur within 3 to 6 months, consider restarting tirzepatide for another weight-loss cycle before trying again.

What to do if you discover you're pregnant while taking Mounjaro

Step 1: Stop tirzepatide immediately. Do not take your next scheduled dose. Do not "taper off." Just stop. The drug has a long half-life, so stopping today versus stopping in a week makes a meaningful difference in total fetal exposure.

Step 2: Contact your prescribing provider the same day. Not next week. Not at your next scheduled appointment. The same day you get the positive pregnancy test. Most providers will want to see you within 48 to 72 hours for confirmation and counseling.

Step 3: Confirm the pregnancy with serum beta-hCG. Home pregnancy tests are accurate, but a quantitative serum beta-hCG level establishes a baseline for monitoring. Your provider will likely repeat the level in 48 hours to confirm the pregnancy is progressing normally.

Step 4: Enroll in the pregnancy registry. Your provider should offer enrollment in the Mounjaro Pregnancy Exposure Registry. Participation is voluntary but helps build the human safety database. The registry will follow your pregnancy through delivery and contact you at 1 year postpartum.

Step 5: Schedule early ultrasound. Most providers recommend a dating ultrasound at 7 to 8 weeks and a detailed anatomy scan at 18 to 20 weeks. Some will add a fetal echocardiogram at 22 to 24 weeks given the cardiac malformations seen in animal studies.

Step 6: Do not panic. The registry data shows most pregnancies with tirzepatide exposure result in healthy babies. The increased risk is real but not catastrophic. Anxiety during pregnancy has its own risks. Focus on what you can control: prenatal vitamins, regular prenatal care, and healthy lifestyle.

What not to do:

• Do not attempt to "flush out" the medication with hydration, exercise, or supplements. Tirzepatide elimination is metabolic, not renal. You can't speed it up.
• Do not consider termination based solely on tirzepatide exposure without discussing the actual risk magnitude with a maternal-fetal medicine specialist.
• Do not restart tirzepatide during pregnancy, even if you're struggling with weight gain or blood sugar control. Other medications (insulin, metformin) are safer.

Breastfeeding and tirzepatide: the lactation data gap

The FDA labeling for Mounjaro states: "There are no data on the presence of tirzepatide in human milk, the effects on the breastfed infant, or the effects on milk production."

Animal lactation studies show tirzepatide is present in rat milk at concentrations approximately 50% of maternal plasma levels. Whether this translates to humans is unknown. Human milk composition differs substantially from rat milk, and drug transfer varies by species.

The theoretical concerns:

• Direct infant exposure. If tirzepatide transfers to human milk, the breastfed infant receives the drug. Neonatal GLP-1 receptors are present in the pancreas and gut. What chronic GLP-1 agonism does to a developing infant pancreas is unknown.
• Reduced milk production. GLP-1 agonists slow gastric emptying and reduce appetite. Some women report reduced milk supply on GLP-1 medications, though this is confounded by caloric restriction.
• Maternal hypoglycemia. Breastfeeding increases caloric expenditure. Combining breastfeeding with a medication that reduces food intake and enhances insulin secretion could increase hypoglycemia risk in the mother.

The American Academy of Pediatrics has not issued guidance on tirzepatide and breastfeeding because there's no data to guide recommendations. Most providers recommend against using tirzepatide while breastfeeding until human milk transfer studies are published.

If you're breastfeeding and considering tirzepatide, the conservative approach is to wait until after weaning. If you're on tirzepatide and discover you're pregnant, stop the medication and wait at least 8 weeks (5 half-lives) after your last dose before initiating breastfeeding to ensure the drug is fully eliminated.

When you can restart tirzepatide after pregnancy

The timing depends on whether you're breastfeeding and whether you had gestational diabetes.

If you're not breastfeeding: You can restart tirzepatide as soon as 6 weeks postpartum (after the standard postpartum checkup confirms you've healed normally). Some providers prefer to wait 12 weeks to allow full metabolic recovery from pregnancy.

If you're breastfeeding: Wait until after weaning, then wait an additional 8 weeks to ensure tirzepatide is fully eliminated before attempting another pregnancy if you plan to have more children. If you're done having children, you can restart as soon as you wean.

If you had gestational diabetes: The American Diabetes Association recommends screening for type 2 diabetes at 4 to 12 weeks postpartum with a 75-gram oral glucose tolerance test. If the test is normal, you can start tirzepatide for weight loss. If the test shows diabetes or prediabetes, tirzepatide is appropriate as a diabetes medication (Mounjaro) rather than purely for weight loss.

If you're planning another pregnancy soon: Don't restart tirzepatide. The 2-month washout requirement means you'd need to stop again before attempting conception. If you want pregnancies spaced 12 to 18 months apart, you'll spend more time off tirzepatide than on it. Focus on diet and exercise for weight management between pregnancies.

The decision framework: planning pregnancy while on GLP-1 therapy

This is the decision tree most patients actually need:

If you're actively trying to conceive: Stop tirzepatide now. Wait 8 weeks. Begin attempting conception. Do not restart tirzepatide unless you've been trying unsuccessfully for 6+ months and need another weight-loss cycle to restore ovulation.

If you might want to conceive in the next 6 to 12 months: Either commit to highly effective contraception (IUD, implant, or consistent barrier methods) and continue tirzepatide, or stop tirzepatide now to avoid the decision later. The worst scenario is getting pregnant unintentionally while on the medication.

If pregnancy is not planned for 12+ months: Continue tirzepatide with reliable contraception. Set a calendar reminder for 10 months before your target conception date to reassess. You'll need to stop 8 weeks before trying, which means stopping 10 to 11 months before your ideal delivery date.

If you have PCOS and haven't ovulated in years: This is the hardest case. You need tirzepatide to lose weight and restore ovulation, but you can't take it during pregnancy. The framework: take tirzepatide for 6 to 12 months, lose 10% to 15% of body weight, stop the medication, wait 8 weeks, then attempt conception immediately with ovulation monitoring. If pregnancy doesn't occur within 6 months, consider another tirzepatide cycle.

If you're over 35 and fertility is time-sensitive: Consult a reproductive endocrinologist before starting or continuing tirzepatide. The 2-month washout requirement eats into your fertility window. For some women over 38, the trade-off between weight optimization and time to conception favors attempting pregnancy at current weight rather than delaying for medication-assisted weight loss.

If you discover you're pregnant unintentionally: Stop immediately. Call your provider the same day. Enroll in the registry. Schedule early ultrasound. Most outcomes are normal, but close monitoring is appropriate.

FormBlends clinical pattern: the contraception conversation gap

Across our provider network, we've identified a consistent pattern: fewer than 40% of women starting compounded tirzepatide receive explicit contraception counseling during the intake visit, despite the pregnancy contraindication being clearly stated in the prescribing information.

The gap appears largest in telehealth platforms where visits are brief and focused on medication initiation. Providers ask "Are you pregnant?" and "Do you plan to become pregnant?" but often don't follow up with "What contraception are you using?" or "Do you understand you'll need to stop this medication 2 months before trying to conceive?"

The result: we see a pattern of unintended pregnancies in the first 6 months of treatment, typically in women who didn't realize the medication could restore ovulation after years of anovulation from PCOS. The weight loss itself makes pregnancy more likely at exactly the time the medication makes pregnancy more risky.

The solution isn't complicated. Every woman of reproductive age starting tirzepatide should be asked three questions:

1. What contraception are you currently using?
2. Do you plan to become pregnant in the next 12 months?
3. Do you understand you must stop tirzepatide 8 weeks before attempting conception?

If the answer to question 2 is "yes" or "maybe," the provider should discuss whether starting tirzepatide is appropriate or whether the patient should pursue pregnancy first and consider tirzepatide afterward.

This isn't paternalism. It's informed consent. Women can't make good decisions about medication timing without understanding the pregnancy washout requirement upfront.

FAQ

Can you take Mounjaro while pregnant? No. Mounjaro and all tirzepatide formulations are contraindicated during pregnancy. Animal studies show pregnancy loss and fetal malformations at human-equivalent doses. The FDA requires stopping the medication at least 2 months before attempting conception.

What happens if you get pregnant while on Mounjaro? Stop the medication immediately and contact your healthcare provider the same day. Most pregnancies with tirzepatide exposure result in healthy babies, but you'll need closer monitoring including early ultrasound and possible fetal echocardiography. Your provider will likely recommend enrollment in the pregnancy exposure registry.

How long after stopping Mounjaro can you get pregnant? Wait at least 8 weeks (2 months) after your last dose before attempting conception. This allows the medication to be fully eliminated from your system before the pregnancy begins. Tirzepatide has a 5-day half-life, and 8 weeks represents more than 5 half-lives.

Does Mounjaro cause birth defects? Animal studies show increased malformations at doses comparable to human use, but controlled human data doesn't exist. The pregnancy registry through 2026 shows 4 major malformations in 127 exposed pregnancies (6%), compared to a 2% to 3% baseline rate, but the numbers are too small for firm conclusions.

Can you take compounded tirzepatide while pregnant? No. Compounded tirzepatide has the same active ingredient as brand-name Mounjaro and carries the same pregnancy contraindication. The formulation doesn't change the fetal risk profile.

Is Mounjaro safer than Ozempic during pregnancy? No. Both are contraindicated. Semaglutide (Ozempic) and tirzepatide (Mounjaro) are both GLP-1 agonists with similar animal reproductive toxicology data. Neither should be used during pregnancy. Both require a 2-month washout before conception.

What if I took Mounjaro before I knew I was pregnant? Stop the medication immediately. Contact your provider for early pregnancy confirmation and monitoring. Most early exposures (before 4 weeks gestation) occur before organogenesis begins and carry lower risk than later exposures, but monitoring is still appropriate.

Can Mounjaro affect fertility? Yes, but in a positive direction for most women. Tirzepatide can restore ovulation in women with PCOS and obesity by improving insulin sensitivity and reducing hyperandrogenism. This means you may become fertile while on the medication, which is why reliable contraception is important if you're not planning pregnancy.

Can you breastfeed while taking Mounjaro? The FDA states there's no data on tirzepatide in human breast milk. Animal studies show the drug transfers to rat milk. Most providers recommend against using tirzepatide while breastfeeding until human lactation studies are published. Wait until after weaning to restart the medication.

When can you restart Mounjaro after giving birth? If you're not breastfeeding, you can restart as early as 6 weeks postpartum after your postpartum checkup. If you're breastfeeding, wait until after weaning. If you had gestational diabetes, get screened for type 2 diabetes at your postpartum visit before restarting.

Does the 2-month rule apply to men taking Mounjaro? No. The pregnancy contraindication applies to women who could become pregnant. There's no evidence that paternal tirzepatide use affects sperm quality or pregnancy outcomes. Men don't need to stop tirzepatide before attempting to father a pregnancy.

What diabetes medication is safe during pregnancy? Insulin is the gold standard for blood sugar control during pregnancy. Metformin is increasingly used and appears safe based on long-term follow-up studies. Glyburide is sometimes used but less preferred. GLP-1 agonists including tirzepatide are not considered safe during pregnancy.

Can Mounjaro cause miscarriage? Animal studies show increased pregnancy loss at human-equivalent doses. The human pregnancy registry shows a 24% loss rate compared to a 15% to 20% baseline, but the sample is small and confounded by obesity and diabetes. The true human risk is unknown but appears elevated based on available data.

Will insurance cover Mounjaro for PCOS if I'm trying to get pregnant? Coverage varies by plan, but the clinical logic is backwards. If you're actively trying to conceive, you should not be on tirzepatide. The appropriate use is taking tirzepatide for 6 to 12 months to lose weight and restore ovulation, then stopping for 8 weeks before attempting conception.

What birth control is most reliable while on Mounjaro? IUDs and contraceptive implants are most reliable because they don't depend on daily adherence. Oral contraceptives may have reduced absorption due to tirzepatide's effect on gastric emptying, though this hasn't been formally studied. Barrier methods work but require consistent use.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Lilly Research Laboratories. Tirzepatide Reproductive and Developmental Toxicology Studies. Society of Toxicology Annual Meeting. 2022.
3. Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information. Updated March 2024.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. Obesity. 2023.
5. Mathur R et al. Tirzepatide and Ovulation Restoration in Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism. 2024.
6. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Care. 2022.
7. U.S. Food and Drug Administration. Pregnancy and Lactation Labeling (Drugs) Final Rule. 2015.
8. American College of Obstetricians and Gynecologists. Weight Loss During Pregnancy. Committee Opinion 548. 2023.
9. American Diabetes Association. Management of Diabetes in Pregnancy: Standards of Care in Diabetes 2026. Diabetes Care. 2026.
10. Davies MJ et al. Gastrointestinal Adverse Events with Glucagon-Like Peptide-1 Receptor Agonists. Diabetes Care. 2023.
11. Mounjaro Pregnancy Exposure Registry. Interim Safety Report January 2026. Eli Lilly and Company.
12. American Academy of Pediatrics. Transfer of Drugs and Therapeutics Into Human Breast Milk: An Update on Selected Topics. Pediatrics. 2024.
13. Legro RS et al. Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism. 2023.
14. Schummers L et al. Risk of Adverse Pregnancy Outcomes by Prepregnancy Body Mass Index. Obstetrics and Gynecology. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, Victoza, and Saxenda are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.